BioCentury | Oct 17, 2019
Emerging Company Profile

Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest

ArsenalBio launched Thursday with $85 million in a series A round to combine the technologies of its six Parker Institute co-founders into a suite of tools the company thinks could overcome key hurdles to cell...
BC Innovations | Oct 15, 2019
Product Development

ImaginAb, pharmas in precompetitive push for T cell imaging biomarker

ImaginAb’s pharma collaboration to develop its CD8 + T cell PET imaging agent is the latest indicator that the best way to develop biomarkers for immuno-oncology is by committee. On Monday, ImaginAb Inc. announced an...
BC Extra | Mar 4, 2019
Company News

Management tracks: Astellas, Sanofi China, Zafgen

Astellas promoted James Kellerman to SVP and head of IP legal and Peter Sandor to SVP and primary focus lead for immuno-oncology. Kellerman was VP of IP, Americas region and Sandor was VP, head of...
BC Extra | Jan 3, 2019
Company News

Management tracks: Portola, Coherus

Hematology company Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said SVP and CMO John Lawrence has resigned to pursue a new position with an undisclosed pharma company. Coherus BioSciences Inc. (NASDAQ:CHRS) hired Darlene Horton as chief medical and...
BC Extra | Oct 2, 2018
Politics & Policy

Nobel Prize goes to discoverers of checkpoint targets

Discoveries that led to a pair of first-in-world approvals for two blockbuster cancer drugs from Bristol-Myers Squibb Co. (NYSE:BMY) and touched off a new era in treating cancer were the focus of this year's Nobel...
BC Extra | Feb 8, 2018
Company News

Management tracks: CRISPR, Arcturus

Gene editing company CRISPR Therapeutics AG (NASDAQ:CRSP) said CSO Bill Lundberg is stepping down. He will become head of CRISPR's scientific advisory board. RNA therapeutics company Arcturus Therapeutics Ltd. (NASDAQ:ARCT) said President and CEO Joseph...
BioCentury | Jan 26, 2018
Finance

Tmunity’s A team

An all-star team with a proven track record in cell therapy enabled Tmunity Therapeutics Inc. to raise a $100 million series A round that included opportunistic investments from non-profits Be the Match BioTherapies and Parker...
BC Week In Review | Jan 18, 2016
Clinical News

IAB2M: Phase I/IIa data

Data from 38 patients with progressive metastatic prostate cancer in an open-label, U.S. Phase I/IIa trial showed that a single IV infusion of IAB2M detected 83.9% of 410 bone lesions vs. 51% of lesions for...
BC Week In Review | Nov 16, 2015
Company News

Eli Lilly, ImaginAb deal

The companies partnered to study T cell-based immuno-oncology therapies. ImaginAb will conduct preclinical studies using IAB22M2C , a CD8 T cell immuno-imaging agent, to detect T cell trafficking and infiltration in response to undisclosed Lilly oncology...
BC Week In Review | Nov 10, 2014
Financial News

Merieux Developpement financial update

Merieux invested EUR70 million ($87.5 million) from its first fund in 12 companies from 2010-14, including neurology company NeuroPhage Pharmaceuticals Inc. (Cambridge, Mass.) and diagnostics company ImaginAb Inc. (Inglewood, Calif.). Merieux Developpement , Lyon, France  ...
Items per page:
1 - 10 of 35
BioCentury | Oct 17, 2019
Emerging Company Profile

Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest

ArsenalBio launched Thursday with $85 million in a series A round to combine the technologies of its six Parker Institute co-founders into a suite of tools the company thinks could overcome key hurdles to cell...
BC Innovations | Oct 15, 2019
Product Development

ImaginAb, pharmas in precompetitive push for T cell imaging biomarker

ImaginAb’s pharma collaboration to develop its CD8 + T cell PET imaging agent is the latest indicator that the best way to develop biomarkers for immuno-oncology is by committee. On Monday, ImaginAb Inc. announced an...
BC Extra | Mar 4, 2019
Company News

Management tracks: Astellas, Sanofi China, Zafgen

Astellas promoted James Kellerman to SVP and head of IP legal and Peter Sandor to SVP and primary focus lead for immuno-oncology. Kellerman was VP of IP, Americas region and Sandor was VP, head of...
BC Extra | Jan 3, 2019
Company News

Management tracks: Portola, Coherus

Hematology company Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said SVP and CMO John Lawrence has resigned to pursue a new position with an undisclosed pharma company. Coherus BioSciences Inc. (NASDAQ:CHRS) hired Darlene Horton as chief medical and...
BC Extra | Oct 2, 2018
Politics & Policy

Nobel Prize goes to discoverers of checkpoint targets

Discoveries that led to a pair of first-in-world approvals for two blockbuster cancer drugs from Bristol-Myers Squibb Co. (NYSE:BMY) and touched off a new era in treating cancer were the focus of this year's Nobel...
BC Extra | Feb 8, 2018
Company News

Management tracks: CRISPR, Arcturus

Gene editing company CRISPR Therapeutics AG (NASDAQ:CRSP) said CSO Bill Lundberg is stepping down. He will become head of CRISPR's scientific advisory board. RNA therapeutics company Arcturus Therapeutics Ltd. (NASDAQ:ARCT) said President and CEO Joseph...
BioCentury | Jan 26, 2018
Finance

Tmunity’s A team

An all-star team with a proven track record in cell therapy enabled Tmunity Therapeutics Inc. to raise a $100 million series A round that included opportunistic investments from non-profits Be the Match BioTherapies and Parker...
BC Week In Review | Jan 18, 2016
Clinical News

IAB2M: Phase I/IIa data

Data from 38 patients with progressive metastatic prostate cancer in an open-label, U.S. Phase I/IIa trial showed that a single IV infusion of IAB2M detected 83.9% of 410 bone lesions vs. 51% of lesions for...
BC Week In Review | Nov 16, 2015
Company News

Eli Lilly, ImaginAb deal

The companies partnered to study T cell-based immuno-oncology therapies. ImaginAb will conduct preclinical studies using IAB22M2C , a CD8 T cell immuno-imaging agent, to detect T cell trafficking and infiltration in response to undisclosed Lilly oncology...
BC Week In Review | Nov 10, 2014
Financial News

Merieux Developpement financial update

Merieux invested EUR70 million ($87.5 million) from its first fund in 12 companies from 2010-14, including neurology company NeuroPhage Pharmaceuticals Inc. (Cambridge, Mass.) and diagnostics company ImaginAb Inc. (Inglewood, Calif.). Merieux Developpement , Lyon, France  ...
Items per page:
1 - 10 of 35